Posts tagged with ‘nutraceutical’

  • Frutarom invests in algae startup for food, cosmetic products

    One of the world’s largest flavoring and specialty natural ingredient companies is investing in algae to enhance its food and cosmetic products. Frutarom Industries said on Monday it bought half of a biotech startup called Algalo, which is based on a kibbutz, or communal farm, in northern Israel, that developed a way to efficiently cultivate, harvest and process a variety […]
    0
  • Fish peptide could help in battle against cardiovascular disease

    A major international review of a peptide originally found in fish that could be used in the battle against cardiovascular disease has been published. Professor David Lambert from the University of Leicester’s Department of Cardiovascular Sciences contributed to the review, which has been largely written by the International Union of Basic and Clinical Pharmacology (IUPHAR) subcommittee, to pull together the […]
    0
  • SGP forms subsidiary, ISG Health, to market algae based nutraceutical products

    International Sustainability Group, Inc. announced the formation of a wholly owned subsidiary, ISG Health to commercialize natural health products. ISG Health is developing a complete line of algae-based nutraceutical products.  These products are designed to support health through a formulation of nature’s minerals, proteins, antioxidants, vitamins and omegas for the health and wellness market.  It is well known that these natural ingredients help with […]
    0
  • Solarvest signs with EU facilities for algal omega-3

    Montague, Prince Edward Island-based Solarvest has signed agreements with two German contract production facilities to accelerate its market presence and meet demand for its Organic Omega products. These facilities will implement Solarvest’s proprietary production process and algae strains to produce high value omega-3 to the company’s specifications. For its neutraceutical applications, the company has specialized in the heterotrophic cultivation of […]
    0
  • First Transnational Joint Call for Research Projects: Marine Biotechnology ERA-NET

    Announcing the first transnational joint call for research projects within the framework of the Marine Biotechnology ERA-NET (ERA-MarineBiotech), which aims to coordinate European funding for marine biotechnology research, development and innovation. The main purpose of the call is to stimulate joint European research and development activities in marine biotechnology. The topic of the first transnational call is “The development of biorefinery processes […]
    0
  • FAO review highlights food and feed uses for fish and shellfish by-products

    By-products may constitute as much as 70% of fish and shellfish after industrial processing and much focus has been on converting these into commercial products. The aim of this paper is therefore to evaluate important challenges and to consider the most realistic options in the use of by-products. Certain by-products like heads, frames and off-cuts from filleting of fish may […]
    0
  • Seaweed an effective alternative for iodine supplementation, study finds

    A study in the British Journal of Nutrition shows that seaweed supplementation can be an effective alternative for boosting the levels of iodine in women deficient in this vital nutrient. More info
    0
  • Mar. Drugs, Volume 12, Issue 5 (May 2014), Pages 2341-3090 Now Available

    MDPI is pleased to announce the publication of the following issue: Mar. Drugs, Volume 12, Issue 5 (May 2014), Pages 2341-3090 More info
    0
  • Fermentalg IPO raises $55.9 million for commercial development

    Libourne, France-based Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, has completed a successful IPO on the Euronext regulated market in Paris, issuing a total of 4,486,091 shares, resulting in a capital increase of €40.4 million ($55.9 million US) and taking the company’s total market capitalization to €107 million ($148 million […]
    0
  • GlycoMar secures £ 890,000 investment

    Scottish marine biotechnology company GlycoMar Ltd has secured investment of £890,000 from new and existing investors. The investment is being used to progress the company’s anti-­‐inflammatory drug development programme. GlycoMar Limited was established in February 2005 and has its premises at the European Centre for  Marine Biotechnology, near Oban, Scotland. GlycoMar, which means ‘sweet sea’, is dedicated to the discovery, development […]
    0